Immunometabolic and Neuro-Ophthalmological Outcomes for 80 RRMS Patients

80 patients with relapsing-remitting multiple sclerosis (RRMS) were analyzed for immunometabolic and neuro-ophthalmological effects of combined therapy. The dataset, authored by Tablo Ahmed Merza Mohammed and last updated in May 2026, includes gene expression, cytokine levels, and optical coherence tomography (OCT) results. It investigates the adjunctive role of Omega-3 supplementation alongside standard pharmacological treatments.

Use Cases

• Analyze correlations between cytokine levels (IL-6, TNF-α, IL-10) and neuro-ophthalmological outcomes based on OCT and VEP parameters mentioned in the description
• Model the relationship between gene expression (BCL2, BAX, CASP3, NRF2, SOD2, AMPK2) and treatment response groups described in the integrated analysis
• Investigate the immunomodulatory effect of Omega-3 based on the described Th1/Th17 ratio and clustering of treatment profiles

Strengths

• Includes data from 80 RRMS patients, providing a basis for statistical analysis
• Combines multiple data modalities: gene expression, cytokine levels, and neuro-ophthalmological measurements (OCT, VEP)
• Released under a permissive CC-BY-4.0 license for reuse

Limitations

• Row count is unknown, which may limit suitability assessment
• Column-level documentation is absent; field semantics must be inferred after download
• Data may reflect temporal or source bias inherent to the single study on figshare

Provenance

Source

figshare

Collection Method

Clinical study assessing peripheral blood mononuclear cells, serum samples, and neuro-ophthalmological tests in RRMS patients.

Freshness

Last updated 2026-05-27 09:19:08; freshness should be verified